UCB SA
UNC
Company Profile
Business description
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
Contact
Allee de la Recherche, 60
BrusselsB-1070
BELT: +32 25599999
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
10,117
Stocks News & Analysis
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
The data and AI company is one of the world’s strongest private companies, but a PitchBook report says it’s unattractive at the current price.
stocks
Takeover proposal agreed for ASX share, other offers permitted
Morningstar analysts’ take on the takeover for this undervalued industrial player.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,951.00 | 31.90 | 0.36% |
| CAC 40 | 8,138.94 | 73.92 | 0.92% |
| DAX 40 | 25,575.01 | 270.95 | 1.07% |
| Dow JONES (US) | 52,048.83 | 366.19 | 0.71% |
| FTSE 100 | 10,739.01 | 79.88 | 0.75% |
| HKSE | 25,048.76 | 6.05 | 0.02% |
| NASDAQ | 27,122.09 | 599.55 | 2.26% |
| Nikkei 225 | 65,018.95 | 882.70 | 1.38% |
| NZX 50 Index | 13,875.48 | 54.28 | 0.39% |
| S&P 500 | 7,764.70 | 114.20 | 1.49% |
| S&P/ASX 200 | 8,757.80 | 25.90 | 0.30% |
| SSE Composite Index | 3,945.42 | 4.49 | -0.11% |